Pfizer

Pfizer is the world's largest ethical pharmaceutical company. The company has a broad portfolio, with strengths in the areas of cardiovascular disease, central nervous system disorders, inflammatory disease, metabolic disorders, infectious diseases and oncology. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.

Headquartered in New York, Pfizer has been the world's largest research-based pharmaceutical company since it stole Merck & Co's crown in 1998. The subsequent acquisition of Warner-Lambert (and with it Agouron) in June 2000 and the merger with Pharmacia in April 2003 (which included the former Monsanto division, GD Searle) cemented this position. Furthermore, in January 2009, the company announced plans to acquire Wyeth, another leading global pharmaceutical company, in a deal valued at around US$68 billion, which should help the company maintain a leaderhsip position in the longer-term.

Pfizer has a broad portfolio, with strengths in the areas of cardiovascular disease, central nervous system disorders, inflammatory disease, metabolic disorders, infectious diseases and oncology.

Employing over 81,000 people worldwide, it has more than 100 overseas subsidiaries and operations in around 150 countries.

Pfizer believes it has one of the broadest product portfolios of all the major pharmaceutical companies. In 2004, Pfizer set an industry record with ten of its products (including Celebrex) generating revenues of more than US$1 billion each; in 2008 this number was reduced to nine.

This new strategic analysis report Pfizer: Pipeline - Products - Performance - Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.